

CHEMISTRY

A European Journal

A Journal of



Accepted Article

Title: Enantioselective Bromolactonization of Trisubstituted Olefinic Acids Catalyzed by Chiral Pyridyl Phosphoramides

Authors: Yasuhiro Nishikawa, Yuhta Hamamoto, Rika Satoh, Naho Akada, Shuhei Kajita, Marina Nomoto, Megumi Miyata, Madoka Nakamura, Chinatsu Matsubara, and Osamu Hara

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: *Chem. Eur. J.* 10.1002/chem.201804630

Link to VoR: <http://dx.doi.org/10.1002/chem.201804630>

Supported by
ACES

WILEY-VCH

Enantioselective Bromolactonization of Trisubstituted Olefinic Acids Catalyzed by Chiral Pyridyl Phosphoramides


Yasuhiro Nishikawa*, Yuhta Hamamoto, Rika Satoh, Naho Akada, Shuhei Kajita, Marina Nomoto, Megumi Miyata, Madoka Nakamura, Chinatsu Matsubara, and Osamu Hara*

Abstract: Enantioselective bromolactonization of trisubstituted olefinic acids producing synthetically useful chiral lactones with two contiguous asymmetric centers has remained mainly unexplored except for the 6-exo cyclization mode. In this work, the 5-exo- and 6-endo modes of bromocyclization of trisubstituted olefinic acids were enabled for the first time using *N*-bromosuccinimide and pyridyl phosphoramidate catalyst. The utility of the resulting bromolactones was demonstrated by transformations harnessing reactive alkyl bromide moieties without losing stereochemical information. Optimization studies and control experiments revealed that the basicity of pyridine moieties and presence of *N*-H protons in phosphoramidate species strongly affected both the reactivity and enantioselectivity parameters.


Enantioselective halocyclization of olefins is an important organic transformation utilized for the construction of chiral heterocyclic compounds containing carbon-halogen bonds.^[1] In 2010, the first successful application of organocatalysis in the asymmetric halolactonization of disubstituted olefins was reported by several groups.^[2] These pioneering works triggered the development of various types of halocyclization reactions involving amides,^[3] carbamates,^[4] alcohols,^[5] and tosylamides^[6]. Among various heterocyclic products synthesized by these methods, chiral halolactones have attracted much attention because lactone derivatives include biologically active compounds and synthetically useful intermediates.^[7] Numerous attempts to enlarge the scope of enantioselective halolactonization have been dedicated to achieving the 5-exo, 6-endo, and 6-exo modes of cyclization using 1,1-disubstituted or 1,2-disubstituted derivatives of olefinic acid.^[2,8-11] On the other hand, the halolactonization process conducted using trisubstituted olefinic acids remains underdeveloped despite its ability to produce various types of lactones containing two contiguous stereocenters with tetrasubstituted carbons. The sole example of a highly enantioselective halolactonization reaction was reported by Fujioka and co-workers, in which 6-exo-cyclization was performed using chiral trisimidazoline catalysts (Scheme 1, Eq. (1)).^[12,13] In contrast, a general method for the 5-exo- and 6-endo-cyclization of trisubstituted olefins via a highly enantioselective bromolactonization reaction has not been

developed yet, although a few examples of 5-exo-cyclization with moderate stereoselectivity were reported (Scheme 1, Eq. (2) and (3)).^[14] In this study, enantioselective bromolactonization reactions with two distinct modes of cyclization enabled using pyridyl phosphoramidate as a single catalyst are described.


6-exo-cyclization: H. Fujioka *et al.* (2012)^[11]



5-exo-cyclization: Several entries in Ref.^[13] **This work**



6-endo-cyclization: unexplored, **This work**



Scheme 1. Several modes of the cyclization reaction enabled via the bromolactonization of trisubstituted olefinic acids.

From the results of our previous study on pyridinium phosphoramidate, we predicted that Brønsted acid catalysts could be utilized for the enantioselective bromolactonization of olefinic acids.^[15] Contrary to our expectations, pyridyl phosphoramidate **1** exhibited much higher reactivity in the preliminary bromolactonization of 1,1-disubstituted alkenoic acid than that of pyridinium phosphoramidate **1•TfOH**; hence, several pyridyl phosphoramidates were screened in this work (Table 1).^[16] As a result, **1a** demonstrated the best catalytic performance in the bromolactonization of (*Z*)-trisubstituted olefinic acid **2a** with *N*-bromosuccinimide (NBS) characterized by good yield and excellent enantioselectivity (entry 1). The *E/Z* ratio of the starting compound **2a** reflected the diastereomeric ratio of the resulting bromolactone **3a**, indicating that the reaction proceeded in a highly diastereoselective manner. The effect of the Lewis basicity of the catalyst was evaluated using catalyst **1a-c** with a substituted pyridine ring. The obtained results suggest that the

Dr. Y. Nishikawa, Y. Hamamoto, R. Sato, N. Akada, S. Kajita, M. Nomoto, M. Miyata, M. Nakamura, C. Matsubara, Prof. Dr. O. Hara
Faculty of Pharmacy
Meijo University
150 Yagotoyama, Tempaku-ku, Nagoya, Aichi 468-8503, Japan
E-mail: yasuhiro@meijo-u.ac.jp; oshara@meijo-u.ac.jp

Supporting information for this article is given via a link at the end of the document.

Table 1. Optimization of the reaction conditions.^[a]

Standard condition

2a (*E* : *Z* = 7 : 93) **3a**

Ar = 4-biphenyl
1a (R = NMe₂)
1b (R = OMe)
1c (R = H)
 Ar = 4-biphenyl
1d

Entry	Variation from standard conditions	3a : Yield [%] ^[b]	ee [%] ^[c]
1	Standard ^[a]	95	92
2	1b (R = OMe) instead of 1a	94	87
3	1c (R = H) instead of 1a	6	85
4	1d instead of 1a	13	5
5	CH ₂ Cl ₂ instead of toluene	73	69
6	THF instead of toluene	8	–
7	Toluene (0.05 M)	95	90
8	Toluene (0.1 M)	98	86
9	DBDMH instead of NBS	86	88
10	–30 °C	84	87
11	–70 °C	4	94
12	5 mol% of 1a	87	88

[a] Reactions were performed by dissolving 0.1 mmol of **2a**, 0.01 mmol of **1a**, and 0.12 mmol of NBS in toluene (4 mL) at –50 °C. See Supporting Information for details. [b] Isolated yields of diastereomer mixtures (*dr* = 96 : 4). [c] Determined by chiral HPLC.

strong Lewis basicity of the pyridine catalyst is essential for achieving high reactivity (entries 1–3). Notably, pyridyl phosphoric ester **1d** without phosphoramidate *N*-H groups showed almost no enantioselectivity (entry 4). These results clearly suggest that the presence of *N*-H protons in phosphoramidate **1a–c** was a critical factor affecting the enantioselectivity of the reaction. The screening of the reaction solvents revealed that toluene produced higher yield and enantioselectivity as compared to

Table 2. Substrates for the 5-exo mode of bromolactonization.^[a]

Standard condition


2a-n **3a-n**

(*E* : *Z* = 1 : >99 ~ 8 : 92)

3a (<i>dr</i> 4 : 96) 95%, 92% ee	3b (<i>dr</i> 9 : 91) 98%, 89% ee	3c (<i>dr</i> 9 : 91) 97%, 95% ee	3d (<i>dr</i> 7 : 93) 95%, 95% ee
3e (<i>dr</i> 7 : 93) 91%, 92% ee	3f (<i>dr</i> 34 : 66) ^[c] 52%, 45% ee	3g (<i>dr</i> 9 : 91) 94%, 94% ee	3h (<i>dr</i> 7 : 93) 89%, 92% ee
3i (<i>dr</i> 1 : <99) 17% ^[b] , ND	3j (<i>dr</i> 1 : <99) 86%, 92% ee	3k (<i>dr</i> 11 : 89) ^[d] 84%, 81% ee	
3l (<i>dr</i> 1 : <99) 99%, 72% ee	3m (<i>dr</i> 4 : 96) 97%, 40% ee	3n (<i>dr</i> 8 : 92) 91%, 47% ee	

[a] Reactions were performed by dissolving 0.1 mmol of **2**, 0.01 mmol of **1a**, and 0.12 mmol of NBS in toluene (4 mL) at –50 °C. See Supporting Information for details. The isolated yields of the diastereomer mixtures are listed. [b] ¹H-NMR yield. [c] The *E/Z* ratio of **2f** was 7/93. [d] The *E/Z* ratio of **2k** was 8/92.

those of relatively polar solvents (entries 5 and 6). In addition, more diluted toluene solutions exhibited higher reaction enantioselectivity values (entries 7 and 8). The use of 1,3-dibromo-5,5-dimethylhydantoin (DBDMH) as a brominating

Table 3. Substrates for the 6-endo mode of bromolactonization.^[a]


[a] Reactions were performed by dissolving 0.1 mmol of **2a**, 0.01 mmol of **1a**, and 0.12 mmol of NBS in toluene (4 mL) at $-20\text{ }^{\circ}\text{C}$. See Supporting Information for details. The isolated yields of the obtained products are listed.

reagent instead of NBS produced a comparable yield with lower selectivity (entry 9). The optimal reaction temperature was equal to $-50\text{ }^{\circ}\text{C}$ (for comparison, the reactions conducted at $-30\text{ }^{\circ}\text{C}$ and $70\text{ }^{\circ}\text{C}$ demonstrated high enantioselectivities and lower yields; see entries 10 and 11). Finally, the catalyst loading could be reduced to 5 mol.% without significant decreases in the yield and selectivity (entry 12).

After performing the stereoselective 5-exo-*dig* bromolactonization of **2a**, we tested the applicability of our method to various trisubstituted alkenoic acids **2b–n** (Table 2). The bromolactonization of (*Z*)-4-aryl-4-hexenoic acids containing various electron withdrawing halogen moieties on their phenyl groups proceeded smoothly with relatively high yields and excellent enantioselectivities (products **3b–d**). The presence of electron donating groups (such as methyl ones) was also tolerated (product **3e**). However, electron-rich groups including the methoxy species of *p*-methoxyphenyl groups had a deleterious effect on both the yield and stereoselectivity,

probably because the Lewis basic olefins activated by these groups were prone to producing racemic bromonium ion intermediates with NBS prior to the interactions with the chiral catalyst **1a** (product **3f**).^[17] On the other hand, the meta-substituted phenyl groups containing both methyl and methoxy moieties resulted in good yields and excellent enantioselectivities (products **3g** and **3h**). The bulky environment of the olefin-containing reaction sites inhibited the bromolactonization reaction, as was shown for the case of *ortho*-substituted derivative **2i** (product **3i**). Subsequently, the substrates having 2-naphthyl, 3-thienyl, or 3-indenyl groups (in addition to phenyl groups) were investigated as well; the resulting bromolactones demonstrated moderate and good enantioselectivities (products **3j–l**). Unfortunately, **2m** containing a cyclohexyl group reacted smoothly, but with low enantioselectivity. For **2i**, the 4-heptenoic acid derivative **2n** having a bulky functional group near the olefin structure produced a low value of ee (product **3n**).

After achieving these results, the 6-endo mode of the enantioselective bromolactonization of (*E*)-trisubstituted olefinic acids was realized. To our delight, the standard conditions for 5-exo-cyclization could be applied for the reaction of 5-phenyl-4-heptenoic acid **4a** by changing the reaction temperature to $-20\text{ }^{\circ}\text{C}$, producing **5a** as a single diastereomer with good yield and excellent enantioselectivity. Both electron withdrawing and donating moieties attached to the para positions of phenyl groups (such as halogens and methyl groups) produced no negative effects, leading to the formation of the cyclized products **5b–d** with high ee values. Moderate enantioselectivity was observed when the substrate **5e** with a *p*-methoxy group was used, probably for the reason suggested for the reaction of **2f**. In contrast, *m*-methoxy derivative **4f** was a good substrate for this system (product **5f**). While the use of *m*-tolyl derivative **4g**

**Scheme 2.** Derivatization of bromolactones **3a** and **5a**.

resulted in a slightly lower enantioselectivity, *o*-tolyl derivative **4h** produced almost racemic compound **5h** with a moderate yield. Likewise, the substrate **5i** containing a bulky ethyl group with a double bond exhibited inferior reactivity and selectivity as compared to those of the methyl derivative **5a**. When R¹ substituent consisted of a methyl, not aromatic group, no control of cyclization regioselectivity was observed, producing a mixture of the 6-membered lactone **5j** and 5-membered lactone **5k** with low to moderate yields and enantioselectivities.

The utility of chiral bromolactones was demonstrated as shown in Scheme 2. Upon the methanolysis of the lactone moieties of **3a** and **5a** by the treatment with Cs₂CO₃ in methanol, the corresponding methyl esters with tertiary alcohols were generated and simultaneously cyclized to produce epoxide **3aa** and **5aa** while retaining the stereochemical information.^[17] In turn, the carbon-halogen bonds of **3a** and **5a** can be reduced selectively under a radical condition, forming the products **3ab** and **5ab** with intact lactone moieties.^[18] Furthermore, the substitution reaction of the neopentyl bromide group in **3a** with

1a, the reactivity of **1a** was compared with that of PPh₃ Lewis base during a short reaction time.^[19] While PPh₃ reacted better in THF than in toluene, **1a** produced lactone **2a** with higher yield in toluene, indicating that the reaction pathway catalyzed by **1a** was different from that catalyzed by PPh₃. In addition, an important structural element in **1a** was elucidated by conducting control experiments involving 4-dimethylaminopyridine (DMAP). To our surprise, the reactions with DMAP in toluene and THF were very slow, suggesting that the simultaneous presence of DMAP and *N*-H species in phosphoramidate moieties was also essential for good reactivity (entries 1, 2, 5, and 6). Furthermore, ¹H-NMR analysis of **2a** with or without one equivalent of **1a** was performed. While the methylene protons in **2a** were observed to be magnetically equivalent as two triplet signals (Figure 1, above), the same protons appeared upfield and magnetically non-equivalent in the presence of **1a** (Figure 1, below). These results indicate that the methylene protons of **2a** become diastereotopic in the chiral environment caused by the complexation of **2a** and chiral pyridylphosphoramidate **1a**.

Table 4. Description of the control experiments.

Entry ^[a]	Catalyst	Solvent	Yield [%] ^[b]	ee [%] ^[c]
1	1a	Toluene	94	90
2	1a	THF	8	-
3	PPh ₃	Toluene	33	-
4	PPh ₃	THF	90	-
5	DMAP	Toluene	15	-
6	DMAP	THF	15	-

[a] Reactions were performed by dissolving 0.1 mmol of **2a** (*E/Z* = 4/96), 0.01 mmol of **1a**, and 0.12 mmol of NBS in toluene (4 mL) at -50 °C. See Supporting Information for details. [b] ¹H-NMR yields as diastereomer mixtures. [c] Determined by chiral HPLC.

sodium azide at the bulky position can be performed to produce the corresponding azide **3ac** in the diastereomerically pure form. Interestingly, the same reaction condition for **5a** resulted in the formation of cyclopropane **5ac** with a relatively low yield; therefore, we deliberately synthesized **5ac** with a good yield by the treatment of DBU in DMF.

To gain mechanistic insights into the bromolactonization reaction catalyzed by the chiral pyridyl phosphoramidate **1a**, several control experiments were performed (Table 4). To evaluate the possibility of the Lewis basic activation of NBS with





Figure 1. ¹H-NMR analysis of the complex of carboxylic acid **2a** and catalyst **1a**.

Based on these data, we proposed a plausible mechanism for the bromolactonization reaction (Scheme 3). We predicted that **1a** might first react with carboxylic acid **2** as a Brønsted base catalyst to form the pyridinium salt **A** through double hydrogen bonding interactions.^[8c,20] The initial pyridinium cation in **A** is transformed to the dimethylammonium cation first and then interact ionically with the carboxylate anion.^[21] The resulting two acidic *N*-H moieties activate the carbonyl group of NBS in a bidentate manner, arranging **2** and NBS in a proximal position (intermediate **B**). It should be noted that the phosphoramidate *N*-H group strongly affected not only the reactivity, but also the enantiodiscriminating step as intermediate **B** (Table 1, entry 4 and Table 4, entry 5). Polar solvents (such as THF) can disturb the ionic and hydrogen bonding interactions in **B** (Table 4, entry

2). Furthermore, the different enantioselectivities obtained using NBS and DBDMH suggest that the brominating reagents are parts of the transition state. Intermediate **B** undergoes bromocyclization to produce **3** and **C**, which release succinimide and catalyst **1a**, thus completing the catalytic cycle.



Scheme 3. A plausible mechanism of the bromolactonization reaction.

In conclusion, the catalytic enantioselective bromocyclization of trisubstituted olefinic acids in both the 5-exo and 6-endo cyclization modes was performed for the first time. In this system, pyridyl phosphoramidate **1a** promotes two different modes of cyclization, producing a variety of bromolactones, which can be further transformed to useful derivatives. The results of optimization and mechanistic studies revealed that **1a** might potentially serve as a dual catalyst activating both carboxylic acid and the brominating reagent simultaneously through ionic and hydrogen bonding interactions. The findings of this study may help to develop a new strategy of catalyst design for promoting asymmetric transformations.

Acknowledgements

Y. Nishikawa thanks Meijo University for financial support.


Keywords: asymmetric catalysis • cyclization • halogenation • lactones • organocatalysis

- [1] For recent reviews, see a) I. Saikia, A. J. Borah, P. Phukan, *Chem. Rev.* **2016**, *116*, 6837; b) U. Hennecke, M. Wilking, *Synlett* **2014**, *25*, 1633; Y. A. Cheng, W. Z. Yu, Y.-Y. Yeung, *Org. Biomol. Chem.* **2014**, *12*, 2333; c) H. Fujioka, K. Murai, *Heterocycles* **2013**, *87*, 763; d) S. E. Denmark, W. E. Kuester, M. T. Burk, *Angew. Chem. Int. Ed.* **2012**, *51*, 10938.
- [2] a) D. C. Whitehead, R. Yousefi, A. Jaganathan, B. Borhan, *J. Am. Chem. Soc.* **2010**, *132*, 3298; b) W. Zhang, S. Zheng, N. Liu, J. B. Werness, I. A. Guzei, W. Tang, *J. Am. Chem. Soc.* **2010**, *132*, 3664; c) L. Zhou, C. K. Tan, X. Jiang, F. Chen, Y.-Y. Yeung, *J. Am. Chem. Soc.* **2010**, *132*, 15474; d) G. E. Veitch, E. N. Jacobsen, *Angew. Chem. Int. Ed.* **2010**, *49*, 7332; *Angew. Chem.* **2010**, *122*, 7490; e) K. Murai, T. Matsushita, A. Nakamura, S. Fukushima, M. Shimura, H. Fujioka, *Angew. Chem. Int. Ed.* **2010**, *49*, 9174; *Angew. Chem.* **2010**, *122*, 9360.
- [3] For recent examples, see a) H. Egami, T. Niwa, H. Sato, R. Hotta, D. Rouno, Y. Kawato, Y. Hamashima, *J. Am. Chem. Soc.* **2018**, *140*, 2785; b) N. Salehi Marzijarani, R. Yousefi, A. Jaganathan, K. D. Ashtekar, J. E. Jackson, B. Borhan, *Chem. Sci.* **2018**, *9*, 2898. c) Y. Kawato, H. Ono, A. Kubota, Y. Nagao, N. Morita, H. Egami, Y. Hamashima, *Chem. Eur. J.* **2016**, *22*, 2127; d) Q. Yin, S.-L. You, *Org. Lett.* **2014**, *16*, 2426; e) A. Jaganathan, R. J. Staples, B. Borhan, *J. Am. Chem. Soc.* **2013**, *135*, 14806; f) Y.-M. Wang, J. Wu, C. Hoong, V. Rauniyar, F. D. Toste, *J. Am. Chem. Soc.* **2012**, *134*, 12928; g) V. Rauniyar, A. D. Lackner, G. L. Hamilton, F. D. Toste, *Science* **2011**, *334*, 1681.
- [4] For recent examples, see a) H. Pan, H. Huang, W. Liu, H. Tian, Y. Shi, *Org. Lett.* **2016**, *18*, 896; b) C.-L. Zhu, J.-S. Tian, Z.-Y. Gu, G.-W. Xing, H. Xu, *Chem. Sci.* **2015**, *6*, 3044; c) A. Garzan, A. Jaganathan, N. S. Marzijarani, R. Yousefi, D. C. Whitehead, J. E. Jackson, B. Borhan, *Chem. Eur. J.* **2013**, *19*, 9015; d) D. Huang, X. Liu, L. Li, Y. Cai, W. Liu, Y. Shi, *J. Am. Chem. Soc.* **2013**, *135*, 8101.
- [5] For recent examples, see a) Y. Lu, H. Nakatsuji, Y. Okumura, L. Yao, K. Ishihara, *J. Am. Chem. Soc.* **2018**, *140*, 6039; b) R. C. Samanta, H. Yamamoto, *J. Am. Chem. Soc.* **2017**, *139*, 1460; c) Z. Shen, X. Pan, Y. Lai, J. Hu, X. Wan, X. Li, H. Zhang, W. Xie, *Chem. Sci.* **2015**, *6*, 6986; d) S. E. Denmark, M. T. Burk, *Chirality* **2014**, *26*, 344; e) Z. Ke, C. K. Tan, F. Chen, Y.-Y. Yeung, *J. Am. Chem. Soc.* **2014**, *136*, 5627; f) S. E. Denmark, M. T. Burk, *Org. Lett.* **2012**, *14*, 256; g) D. Huang, H. Wang, F. Xue, H. Guan, L. Li, X. Peng, Y. Shi, *Org. Lett.* **2011**, *13*, 6350; h) U. Hennecke, C. H. Müller, R. Fröhlich, *Org. Lett.* **2011**, *13*, 860.
- [6] a) F. Chen, C. K. Tan, Y.-Y. Yeung, *J. Am. Chem. Soc.* **2013**, *135*, 1232; b) M. T. Bovino, S. R. Chemler, *Angew. Chem. Int. Ed.* **2012**, *51*, 3923; *Angew. Chem.* **2012**, *124*, 3989; c) L. Zhou, J. Chen, C. K. Tan, Y.-Y. Yeung, *J. Am. Chem. Soc.* **2011**, *133*, 9164.
- [7] a) P. M. Dewick, *Medicinal Natural Products: A Biosynthetic Approach*, 3rd Ed. Wiley-VCH, Weinheim, **2009**; b) P. Allevi, M. Anastasia, P. Ciuffreda, E. Bigatti, P. Macdonald, *J. Org. Chem.* **2015**, *6*, 4175; c) A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, *et al.*, *Proc. Natl. Acad. Sci.* **1980**, *77*, 3957.
- [8] For recent examples of 5-exo and 6-endo cyclization, see a) X. Jiang, S. Liu, S. Yang, M. Jing, L. Xu, P. Yu, Y. Wang, Y.-Y. Yeung, *Org. Lett.* **2018**, *20*, 3259; b) D. W. Klosowski, J. C. Hethcox, D. H. Paull, C. Fang, J. R. Donald, C. R. Shugrue, A. D. Pansick, S. F. Martin, *J. Org. Chem.* **2018**, *83*, 5954; c) M. T. Knowe, M. W. Danneman, S. Sun, M. Pink, J. N. Johnston, *J. Am. Chem. Soc.* **2018**, *140*, 1998; d) F. Gelat, M. Coffinet, S. Lebrun, F. Agbossou-Niedercorn, C. Michon, E. Deniau, *Tetrahedron: Asymmetry* **2016**, *27*, 980; e) H. Egami, J. Asada, K. Sato, D. Hashizume, Y. Kawato, Y. Hamashima, *J. Am. Chem. Soc.* **2015**, *137*, 10132; f) R. Yousefi, K. D. Ashtekar, D. C. Whitehead, J. E. Jackson, B. Borhan, *J. Am. Chem. Soc.* **2013**, *135*, 14524;
- [9] For recent examples of 6-exo cyclization, see a) M. Aursnes, J. E. Tungen, T. V. Hansen, *J. Org. Chem.* **2016**, *81*, 8287; b) T. Arai, N. Sugiyama, H. Masu, S. Kado, S. Yabe, M. Yamanaka, *Chem. Commun.* **2014**, *50*, 8287; c) T. Arai, S. Kajikawa, E. Matsumura, *Synlett* **2013**, *24*, 2045; d) K. Murai, T. Matsushita, A. Nakamura, N. Hyogo, J. Nakajima, H. Fujioka, *Org. Lett.* **2013**, *15*, 2526.
- [10] For examples of halolactonization of allenic acids, see a) K. Murai, N. Shimizu, H. Fujioka, *Chem. Commun.* **2014**, *50*, 12530; b) M. Wilking, C. Daniliuc, U. Hennecke, *Synlett* **2014**, *25*, 1701.
- [11] J. D. Griffin, C. L. Cavanaugh, D. A. Nicewicz, *Angew. Chem. Int. Ed.* **2017**, *56*, 2097; *Angew. Chem.* **2017**, *129*, 2129.

- [12] K. Murai, A. Nakamura, T. Matsushita, M. Shimura, H. Fujioka, *Chem. Eur. J.* **2012**, *18*, 8448–8453.
- [13] One entry of bromolactonization of a trisubstituted olefin leading to a bromoallene was reported; see the reference 2b.
- [14] a) A. Armstrong, D. C. Braddock, A. X. Jones, S. Clark, *Tetrahedron Lett.* **2013**, *54*, 7004; b) K. Ikeuchi, S. Ido, S. Yoshimura, T. Asakawa, M. Inai, Y. Hamashima, T. Kan, *Org. Lett.* **2012**, *14*, 6016; c) D. H. Paull, C. Fang, J. R. Donald, A. D. Pansick, S. F. Martin, *J. Am. Chem. Soc.* **2012**, *134*, 11128.
- [15] Y. Nishikawa, S. Nakano, Y. Tahira, K. Terazawa, K. Yamazaki, C. Kitamura, O. Hara, *Org. Lett.* **2016**, *18*, 2004.
- [16] a) Y. Toda, M. Pink, J. N. Johnston, *J. Am. Chem. Soc.* **2014**, *136*, 14734; b) M. C. Dobish, J. N. Johnston, *J. Am. Chem. Soc.* **2012**, *134*, 6068.
- [17] R. S. Brown, *Acc. Chem. Res.* **1997**, *30*, 131.
- [18] See Supporting Information for the discussion on the relative and absolute configuration of **3aa**, **5aa**, **3ab** and **5ab**.
- [19] S. E. Denmark, M. T. Burk, *Proc. Natl. Acad. Sci.* **2010**, *107*, 20655.
- [20] a) K. D. Ashtekar, M. Vetticatt, R. Yousefi, J. E. Jackson, B. Borhan, *J. Am. Chem. Soc.* **2016**, *138*, 8114; b) M. Wilking, C. G. Daniliuc, U. Hennecke, *Chem. Eur. J.* **2016**, *22*, 18601.
- [21] Y. A. Cheng, T. Chen, C. K. Tan, J. J. Heng, Y.-Y. Yeung, *J. Am. Chem. Soc.* **2012**, *134*, 16492.

Layout 2:

COMMUNICATION



Dr. Y. Nishikawa*, Y. Hamamoto, R. Satoh, N. Akada, S. Kajita, M. Nomoto, M. Miyata, M. Nakamura, C. Matsubara and Dr. O. Hara*

Page No. – Page No.

Enantioselective Bromolactonization of Trisubstituted Olefinic Acids Catalyzed by Chiral Pyridyl Phosphoramides

Enantioselective bromolactonization of trisubstituted olefinic acids producing synthetically useful chiral lactones with two contiguous asymmetric centers was performed. The use of pyridyl phosphoramidate as a Brønsted base catalyst enabled the 5-exo and 6-endo modes of bromolactonization leading to the formation of a variety of chiral lactones, which can be transformed to synthetically useful compounds.

Accepted Manuscript